Primary Immunodeficiency Therapeutics Market by Disease Type and Geography - Forecast and Analysis 2022-2026

The predicted growth for the primary immunodeficiency therapeutics market from 2021 to 2026 is USD 3.13 billion at a progressing CAGR of 7.73%.

This primary immunodeficiency therapeutics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. The primary immunodeficiency therapeutics market report offers information on several market vendors, including ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd. among others.

This report further entails primary immunodeficiency therapeutics market segmentations, including:

• Disease type - Antibody deficiency, cellular immunodeficiency, and innate immune disorders
• Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Primary Immunodeficiency Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Primary Immunodeficiency Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Primary Immunodeficiency Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing prevalence of immunodeficiency diseases is notably driving the primary immunodeficiency therapeutics market growth, although factors such as side effects of immunotherapy may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the primary immunodeficiency therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Primary Immunodeficiency Therapeutics Market Driver

• The increasing prevalence of immunodeficiency diseases is one of the key drivers supporting the primary immunodeficiency therapeutics market growth.
• Adenosine deaminase deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide.
• According to the data released by the World Health Organization (WHO) in November 2020, around 1.5 million new human immunodeficiency virus (HIV) infections were reported globally.
• The prevalence of PIDDs in the US is estimated at 1 in 2000 individuals. While quick evaluation by an immunologist is important for timely diagnosis and treatment, these patients are typically first evaluated by other sub-specialists or primary care providers. Thus, the increasing prevalence of immunodeficiency diseases is expected to drive the primary immunodeficiency therapeutics market growth during the forecast period. 

Key Primary Immunodeficiency Therapeutics Market Trend

• Increasing R&D activities is one of the key primary immunodeficiency therapeutics market trends contributing to the market growth.
• According to an investigational research study conducted in the US and the UK and supported by the NIH in May 2021, 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function.
• R&D will continue to be critical in improving the chances of new primary immunodeficiency treatments and therapies. To achieve a competitive advantage in today's market, companies should ideally focus on the development of custom-made medicines for primary immunodeficiency diseases. 
• People diagnosed with a primary immunodeficiency disease are benefiting from PIDD R&D, which is improving treatment options for patients, making significant progress in recovery, and improving the quality of life of patients. This, in turn, will fuel the primary immunodeficiency therapeutics market growth during the forecast period.

Key Primary Immunodeficiency Therapeutics Market Challenge

• Side effects of immunotherapy is one of the challenges hindering the primary immunodeficiency therapeutics market growth.
• Side effects can occur at any point during and after treatment. Doctors and nurses cannot predict when or if side effects may occur or the severity of those consequences.
• Immunotherapy side effects vary by treatment type and can also be influenced by the patient's overall health and the location and type of cancer.
• Some immunotherapies can result in severe, even fatal allergic and inflammatory reactions. Therefore, the side effects of immunotherapy may hinder the growth of the global primary immunodeficiency therapeutics market during the forecast period. 

This primary immunodeficiency therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global primary immunodeficiency therapeutics market as a part of the pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the primary immunodeficiency therapeutics market during the forecast period.

Who are the Major Primary Immunodeficiency Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• ADMA Biologics Inc.
• Astellas Pharma Inc.
• Baxter International Inc.
• Bayer AG
• Bio Products Laboratory Ltd.
• Biocon Ltd.
• Biotest AG
• CSL Ltd.
• Grifols SA
• Kedrion Spa
• LFB SA
• Lupin Ltd.
• Octapharma AG
• Pfizer Inc.
• Sanquin
• Takeda Pharmaceutical Co. Ltd.

 

This statistical study of the primary immunodeficiency therapeutics market encompasses successful business strategies deployed by the key vendors. The primary immunodeficiency therapeutics market is fragmented and the vendors are deploying growth strategies such as partnership, agreement, collaboration, and joint ventures to compete in the market.

Product Insights and News

• Bayer.com - The company offers primary immunodeficiency therapeutics that enable the body to produce the required proteins itself.
• Bplgroup.com - The company offers primary immunodeficiency therapeutics that are used in the treatment of chronic viral infectious diseases.
• Biocon.com - The company offers primary immunodeficiency therapeutics that is widely distributed to normal tissues, including the thymus, spleen and skin.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Primary Immunodeficiency Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the primary immunodeficiency therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The primary immunodeficiency therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.

Which are the Key Regions for Primary Immunodeficiency Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the primary immunodeficiency therapeutics market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The increasing prevalence of immunodeficiency diseases and technological advancements in genetic and stem cell therapy will facilitate the primary immunodeficiency therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 outbreak in 2020 certainly had a negative impact on the primary immunodeficiency therapeutics market in North America. However, in 2021, the demand for these products rebounded, as manufacturing activities were reopened due to large-scale COVID-19 vaccination drives. These factors are expected to drive the growth of the regional primary immunodeficiency therapeutics market during the forecast period.

What are the Revenue-generating Disease Type Segments in the Primary Immunodeficiency Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The primary immunodeficiency therapeutics market share growth by the antibody deficiency segment will be significant during the forecast period. The most common type of primary immunodeficiency in humans is antibody deficiency. It is a diverse category of diseases that cause the malfunction of one or more components of the immune system. Different parts of the immune system are affected by different types of primary immunodeficiency diseases. Antibody deficiency disorders, also known as humoral immunodeficiency diseases, primarily affect B cells. About half of the patients diagnosed with a primary immunodeficiency disease also have a primary antibody deficiency disorder. Such factors of antibody deficiency will drive the primary immunodeficiency therapeutics market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the primary immunodeficiency therapeutics market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Primary Immunodeficiency Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 7.73%
Market growth 2022-2026	$3.13 billion
Market structure	Fragmented
YoY growth (%)	5.3
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Primary Immunodeficiency Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive primary immunodeficiency therapeutics market growth during the next five years
• Precise estimation of the primary immunodeficiency therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the primary immunodeficiency therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of primary immunodeficiency therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch